Related Experiment Video
Updated: Dec 8, 2025

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
Published on: May 21, 2018
SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
V Quagliariello1, A Bonelli, A Caronna
1Division of Cardiology, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy. quagliariello.enzo@gmail.com.
Abstract:
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

